158 related articles for article (PubMed ID: 10994663)
41. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
42. Which patients with prostatic carcinoma require a staging bone scan?
Kemp PM; Maguire GA; Bird NJ
Br J Urol; 1997 Apr; 79(4):611-4. PubMed ID: 9126094
[TBL] [Abstract][Full Text] [Related]
43. Discrepancy between clinical symptoms and Tc-99m MDP bone scan findings before and after strontium-89 therapy for metastatic bone pain of prostate carcinoma.
Sun SS; Tsai SC; Hsieh JF; Lee JK; Kao CH
Clin Nucl Med; 2001 Feb; 26(2):167-9. PubMed ID: 11201488
[No Abstract] [Full Text] [Related]
44. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
45. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.
Gleave ME; Coupland D; Drachenberg D; Cohen L; Kwong S; Goldenberg SL; Sullivan LD
Urology; 1996 May; 47(5):708-12. PubMed ID: 8650870
[TBL] [Abstract][Full Text] [Related]
46. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
47. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.
Al-Ghazo MA; Ghalayini IF; Al-Azab RS; Bani-Hani I; Barham A; Haddad Y
Int Braz J Urol; 2010; 36(6):685-91; discussion 691-2. PubMed ID: 21176275
[TBL] [Abstract][Full Text] [Related]
48. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
49. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
[TBL] [Abstract][Full Text] [Related]
50. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.
Kane CJ; Amling CL; Johnstone PA; Pak N; Lance RS; Thrasher JB; Foley JP; Riffenburgh RH; Moul JW
Urology; 2003 Mar; 61(3):607-11. PubMed ID: 12639656
[TBL] [Abstract][Full Text] [Related]
51. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
[TBL] [Abstract][Full Text] [Related]
52. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
53. The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly diagnosed prostate carcinoma.
Stokkel MP; Zwinderman AH; Zwartendijk J; Pauwels EK; Van Eck-Smit BL
Int J Biol Markers; 1998; 13(2):70-6. PubMed ID: 9803354
[TBL] [Abstract][Full Text] [Related]
54. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
55. Preserved value of bone scintigraphy for the detection of skeletal metastases in prostate cancer patients with low prostate-specific antigen levels: effect of hormonal therapy and poor histologic differentiation.
Caglar M; Tuncel M
Clin Nucl Med; 2002 Jul; 27(7):532-3. PubMed ID: 12072787
[No Abstract] [Full Text] [Related]
56. Higher scrotal uptake ratio of (99m)Tc-MDP on bone scans in newly diagnosed prostate cancer: a reliable indicator of pelvic node metastasis.
Zaman MU; Fatima N; Sajjad Z; Hashmi I; Khan K
Ann Nucl Med; 2012 Oct; 26(8):676-80. PubMed ID: 22777858
[TBL] [Abstract][Full Text] [Related]
57. Bone scan in initial staging of prostate cancer.
Boughattas S; Letaief B; Hassine H; Chatti K; Essabah H
Tunis Med; 2003 Jun; 81(6):400-6. PubMed ID: 14534946
[TBL] [Abstract][Full Text] [Related]
58. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
[TBL] [Abstract][Full Text] [Related]
59. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
[TBL] [Abstract][Full Text] [Related]
60. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ
BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]